Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

NCT05518357 is registered in ClinicalTrials.gov with Hebei Yanda Ludaopei Hospital as lead sponsor.

NCT NCT05518357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05518357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Lead sponsor
Hebei Yanda Ludaopei Hospital
Phase
Phase 1
Overall status
Completed
Start date
June 24, 2022
Completion date
November 15, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia